AL amyloidosis
Therapeutic area
Neurology
Rare disease
Yes
- Definition
- AL Amyloidosis is a plasma cell disorder characterized by the aggregation and deposition of insoluble amyloid fibrils derived from misfolding of monoclonal immunoglobulin light chains usually produced by a plasma cell tumor. It usually presents as primary systemic amyloidosis (PSA) with multiple organ involvement and less frequently as primary localized amyloidosis (PLA) restricted to a single organ.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- AL amyloidosis
- Therapeutic area
- Neurology
- AL amyloidosis
- AL Amyloidosis (AL)
- Light Chain (AL) Amyloidosis
- Light Chain (AL) Amyloidosis, Stage 3B
- Light Chain Amyloidosis
- Light-chain amyloidosis
- Newly Diagnosed Primary Amyloidosis
- primary amyloidosis
- Recurrent AL Amyloidosis
- Recurrent Primary Amyloidosis
- Refractory AL Amyloidosis
- Refractory Primary Amyloidosis
- Relapsed AL Amyloidosis
- amyloidosis AL
- amyloidosis primary systemic
- primary AL amyloidosis
- primary systemic AL amyloidosis
- primary systemic amyloidosis
- systemic AL amyloidsis
- Severity
- Severe
- Cardiology
- Metabolic Disease
- Neurology
- Neuromuscular Disease
- Rheumatology
Sources for recorded values
- MONDO ID
- MONDO:0019438
- Parent condition
- MONDO:0005071
Related records
Broader conditions (20)
- Acquired metabolic disease
- Amyloidosis
- Cardiomyopathy
- Cardiovascular disorder
- Disease
- Disease by body system or component
- Disease by developmental or physiological process
- Disease by molecular mechanism
- Heart disorder
- Human disease
- Hypertrophic cardiomyopathy
- Intrinsic cardiomyopathy
- Metabolic disease
- Muscle tissue disorder
- Musculoskeletal system disorder
- Nervous system disorder
- Non-familial hypertrophic cardiomyopathy
- Non-familial restrictive cardiomyopathy
- Proteostasis deficiencies
- Restrictive cardiomyopathy
Narrower conditions (2)
- Primary localized amyloidosis
- Primary systemic amyloidosis
Trials (249)
- 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder
- 124I-p5+14 Injection Safety in Subjects With Systemic Amyloidosis
- 2nd Autologous Stem Cell Transplant in Patients With Persistent/Recurrent (AL) Amyloidosis
- 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
- 4'-Iodo-4'-Deoxydoxorubicin in Treating Patients With Primary Systemic Amyloidosis
- 506U78 in Treating Patients With Hematologic Cancer and Kidney or Liver Impairment
- A Clinical Study of Melphalan Flufenamide (Melflufen) and Dexamethasone for Patients With Immunoglobulin Light Chain (AL) Amyloidosis
- A Clinical Study on Minimal Residual Disease in Patients With Systemic Light Chain Amyloidosis
- A Dose Escalation Study of Carfilzomib Taken With Thalidomide and Dexamethasone in Relapsed AL Amyloidosis
- A EUropean REgistry and Sample Sharing networK to Promote the Diagnosis and Management of Light Chain Amyloidosis (EUREKA)
- A Phase 1 Study of 99mTc-p5+14 in Healthy Volunteers and Patients With AL or ATTR Systemic Amyloidosis
- A Phase 1b/2 Study of CAR T Cell Therapy Targeting CD19 and BCMA in Participants With Relapsed or Refractory AL Amyloidosis.
- A Phase I/II Open-label, Single-arm, Multicenter Clinical Study to Evaluate the Safety and Efficacy of FKC289 in Subjects With Relapsed/Refractory Primary AL Amyloidosis
- A Phase I/II Trial of Pomalidomide and Dexamethasone in Subjects With Previously-Treated AL Amyloidosis
- A Phase II Study to Evaluate the Efficacy and Safety of Teclistamab in Combination With Daratumumab (Tec-Dara) in Newly Diagnosed Multiple Myeloma With Concurrent Light Chain Amyloidosis (MM+AL).
- A Phase II Trial of Teclistamab in Participants With Previously Treated Immunoglobulin Light-chain (AL) Amyloidosis
- A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
- A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis
- A Registry of AL Amyloidosis (ReAL)
- A Registry of Chinese AL Amyloidosis Patients Treated With Subcutaneous or Intravenous Daratumumab
Approved drugs (2)
- Tafamidis
- Tafamidis meglumine
Drugs in development (38)
- Amiodarone Phase 2
- Amiodarone hydrochloride Phase 2
- Anselamimab Phase 3
- Belantamab mafodotin Phase 2
- Bendamustine Phase 2
- Bendamustine hydrochloride Phase 2
- Birtamimab Phase 3
- Bortezomib Phase 3
- Bortezomib D-mannitol Phase 1
- Carfilzomib Phase 1
- Coagulation factor X human Phase 3
- Cyclophosphamide Phase 3
- Dapagliflozin Phase 2
- Daratumumab Phase 3
- Dexamethasone Phase 3
- Doxycycline Phase 2
- Elotuzumab Phase 2
- Elranatamab Phase 1
- Epigalocatechin gallate Phase 2
- Equecabtagene autoleucel Phase 2
Other linked drugs (2)
- Antilymphocyte immunoglobulin (horse)
- Tacrolimus